Duodenal-jejunal Bypass Sleeve (DJBS) for Obesity and Metabolic Syndrome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorChinese University of Hong Kong
About this trial
This study is designed to evaluate the efficacy, safety, and mechanisms of duodenal-jejunal bypass sleeve in patients with obesity
Eligibility criteria
Qualifiers
Body mass index (BMI) ≥27.5kg/m2; or BMI ≥25 kg/m2 with metabolic syndrome
Disqualifiers
Patients who have lost more than 5 kg of weight in the past three months
Patients who have used glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the past three months
Patients who are currently taking weight loss drugs such as orlistat
Those who have taken antiplatelet drugs or anticoagulant drugs such as aspirin in the past month
Trial design
Treatments tested in this trial
- Implantation of duodenal-jejunal bypass sleeve
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
2Chinese University of Hong Kong Shatin Hong Kong
CUHK Medical Centre Shatin Hong Kong
Sponsors and collaborators
Chinese University of Hong Kong
Lead sponsor
CUHK Medical Centre
Collaborator
Source ClinicalTrials.gov